NPM1 and acute myeloid leukemia: Furthermore, the combination of ATRA and arsenic trioxide (ATO) synergistically promotes the proteasomal degradation of the mutant NPM1 protein with an unclear mechanism, resulting in leukemic cell differentiation, growth inhibition and apoptosis in NPM1-mutated AML treated with daunorubicin [137,138,139].